Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-25-000199
Filing Date
2025-02-19
Accepted
2025-02-19 17:52:03
Documents
1
Period of Report
2025-02-14

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 14469
  Complete submission text file 0000947871-25-000199.txt   17199
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-42272 | Film No.: 25642089

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6491
OrbiMed Capital GP VII LLC (Reporting) CIK: 0001760648 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-42272 | Film No.: 25642088

Mailing Address 12406 HORESHAM STREET CARMEL IN 46032
Business Address 12406 HORESHAM STREET CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Issuer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
OrbiMed Genesis GP LLC (Reporting) CIK: 0001808744 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-42272 | Film No.: 25642087